A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer

European Journal of Cancer

Volumn 47, Issue 2, 2011, Pages 199-205

  Infante, Jeffrey R ^a,b   Jones, Suzanne F ^a   Bendell, Johanna C ^a,b   Spigel, David R ^a,b   Yardley, Denise A ^a,b   Weekes, Colin D ^c   Messersmith, Wells A ^c   Hainsworth, John D ^a,b   Burris III, Howard A ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

CA 19 9 antigen; Immunomodulatory therapy; Pancreatic neoplasms; Pomalidomide

Indexed keywords

FLUOROURACIL; GEMCITABINE; IMID; POMALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OPTIMAL DRUG DOSE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VOMITING; WEAKNESS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 78650697068     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.09.002     Document Type: Article

References (23)

1. E.P. DiMagno, H.A. Reber, and M.A. Tempero AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association Gastroenterology 117 6 1999 1464 1484
2. R.J. Geer, and M.F. Brennan Prognostic indicators for survival after resection of pancreatic adenocarcinoma Am J Surg 165 1 1993 68 72 [discussion 72-3]
3. W.F. Regine, K.W. Winter, and R. Abrams RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma J Clin Oncol 24 Suppl. 18 2006 4007 [ASCO Meeting Abstracts]
4. T.A. Sohn, C.J. Yeo, and J.L. Cameron Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 6 2000 567 579
5. Ries L, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review 1975-2003; 2006.
6. H.A. Burris 3rd, M.J. Moore, and J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 1997 2403 2413
7. J. Tabernero, and T. Macarulla Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development J Clin Oncol 27 33 2009 5487 5491
8. D. Cunningham, I. Chau, and D.D. Stocken Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 33 2009 5513 5518
9. R. Herrmann, G. Bodoky, and T. Ruhstaller Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 16 2007 2212 2217
10. W. Scheithauer, B. Schull, and H. Ulrich-Pur Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial Ann Oncol 14 1 2003 97 104
11. M.J. Moore, D. Goldstein, and J. Hamm Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 15 2007 1960 1966
12. J.B. Bartlett, K. Dredge, and A.G. Dalgleish The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 4 2004 314 322
13. M.W. Saif Anti-angiogenesis therapy in pancreatic carcinoma JOP 7 2 2006 163 173
14. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
15. S.A. Schey, P. Fields, and J.B. Bartlett Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma J Clin Oncol 22 16 2004 3269 3276
16. M.M. Cooney, J.A. Bokar, and R. Dreicer Phase I trial of daily pomalidomide in patients with advanced solid tumors J Clin Oncol 28 Suppl. 15 2010 e13077 [ASCO Meeting Abstracts]
17. E. Poplin, Y. Feng, and J. Berlin Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group J Clin Oncol 27 23 2009 3778 3785
18. E. Van Cutsem, W.L. Vervenne, and J. Bennouna Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer J Clin Oncol 27 13 2009 2231 2237
19. A.A. Khorana, and R.L. Fine Pancreatic cancer and thromboembolic disease Lancet Oncol 5 11 2004 655 663
20. H. Riess, U. Pelzer, and G. Deutschinoff A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial J Clin Oncol 27 18S 2009 LBA4506 [ASCO Meeting Abstracts]
21. H.L. Kindler, G. Friberg, and D.A. Singh Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer J Clin Oncol 23 31 2005 8033 8040 (Pubitemid 46657405)
22. H.L. Kindler, D. Niedzwiecki, and D. Hollis A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB J Clin Oncol 25 Suppl. 18 2007 4508 [ASCO Meeting Abstracts]
23. H.L. Kindler, T. Ioka, and D.J. Richel 6502 A double-blinded, placebo-controlled, randomized, phase III study of axitinib (AG-013736; A) plus gemcitabine (G) vs. G plus placebo (P) in advanced pancreatic cancer (PC) patients (pts) Eur J Cancer Suppl 7 2 2009 361 362